Why Cardiff Oncology, Inc.’s (CRDF) Stock Is Up 5.17%
As of Tuesday, September 01, Cardiff Oncology, Inc.’s CRDF share price has surged by 5.17%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Commentary & Analysis
Why Cardiff Oncology, Inc.’s (CRDF) Stock Is Up 5.71%
As of Tuesday, August 25, Cardiff Oncology, Inc.’s CRDF share price has surged by 5.71%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Cardiff Oncology, Inc.’s (CRDF) Stock Is Up 15.79%
As of Monday, August 24, Cardiff Oncology, Inc.’s CRDF share price has surged by 15.79%, which has investors questioning if this is right time to sell.Michael Rose
Why Cardiff Oncology, Inc.’s (CRDF) Stock Is Up 14.76%
As of Monday, August 24, Cardiff Oncology, Inc.’s CRDF share price has surged by 14.76%, which has investors questioning if this is right time to sell.Omar Beirat
Why Cardiff Oncology, Inc.’s (CRDF) Stock Is Up 6.39%
As of Monday, August 03, Cardiff Oncology, Inc.’s CRDF share price has surged by 6.39%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | CRDF | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $82.5 | $288.9 | 19% |
|
| Shares Out (Mil) | 68.4 | 54.0 | 55% |
|
| Institutional Ownership | 88.5% | 93.1% | 56% |
|
| Float (Mil) | 75.4 | 41.4 | 56% |
|
| Beta | 1.44 | 0.94 | 81% |
|
| Avg Daily Volume (000s) | 695 | 480 | 65% |
|
| Price Change (52-week) |
(45.6%) | 59.9% | 17% |
|
| Growth | CRDF | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 8.4% | 14.1% | 52% |
|
| Net Income (5yr) | (18.9%) | (10.1%) | 21% |
|
| EPS (5yr) | 8.7% | 15.9% | 44 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.9%) | (15.6%) | 46% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 3 | |
| Current EPS | ($0.130) | ($0.563) | ($0.603) | |
| Month Ago EPS | ($0.168) | ($0.687) | ($0.814) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.168) | ($0.687) | ($0.816) | |
| Year/Year Chg | (3.7%) | (17.9%) | 21.7% | |
| Financials | CRDF | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $37 | 1% |
|
| Net Income (TTM) (Mil) | ($40) | ($43) | 18% |
|
| EPS (TTM) | ($0.591) | ($1.500) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($41) | ($31) | 11% |
|
| Net Cash Flow (TTM) (Mil) | ($2) | $2 | 38% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $37 | $190 | 14% |
|
| Valuation | CRDF | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.72 | 2.84 | 61% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CRDF | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (70.8%) | (47.7%) | 8% |
|
| ROE | (94.1%) | (55.0%) | 10% |
|
| Liabilities to Assets | 28.9% | 29.6% | 20% |
|
| F-Score | 3 | 3 | 18% |
|
Cardiff Oncology, Inc. did not pass any screens on 9/2/2026.
